Neuroendocrine tumor staging with Gallium-68 positron emission tomography/ computed tomography
Keywords:
Positron emission tomography, Neuroendocrine tumor, StagingAbstract
Well-differentiated neuroendocrine tumors are very uncommon neoplasms. Most of them are diagnosed in advanced stages. The only complete treatment is surgical resection of the primary tumor, but patients are not often found at initial states. Given that welldifferentiated tumors have receptors for somatostatin and over-express predominantly receptor 2, nuclear medicine research has developed specific molecular probes that target these cell receptors and are linked to radiation emitters for proper localization, staging and treatment (radiolabeled somatostatin analogues). Among these, studies using PET-Gallium68 DOTATATE, DOTATOC or DOTANOC have been established as the most effective imaging diagnostic tool, due to its high ability to detect both the primary tumor and metastases.
Author Biography
Alejandro Martí Samper, Instituto Nacional de Cancerología
Médico nuclear, Grupo de Medicina Nuclear-PET, Instituto Nacional de Cancerología, Bogotá, Colombia
References
Baum RP , Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics. 2012;2:437-47.
https://doi.org/10.7150/thno.3645
Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42:190-207.
https://doi.org/10.1053/j.semnuclmed.2012.01.002
Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single center study. AJR Am J Roentgenol. 2011;197:1221-8.
https://doi.org/10.2214/AJR.11.7298
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68) Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
https://doi.org/10.1007/s00259-009-1205-y
Srirajaskanthan R, Kayani I, Quigley AM. The role of 68GaDOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In- DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875-82.
https://doi.org/10.2967/jnumed.109.066134
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2013. [Pendiente de publicación electronica].
https://doi.org/10.1177/0284185113496679
Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-7.
https://doi.org/10.1007/s12020-012-9631-1
Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S52-60.
https://doi.org/10.1007/s00259-011-1989-4
Oberg K. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics. 2012;2:448-58.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
